Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany

JDDG - Journal of the German Society of Dermatology

Volumn 3, Issue 7, 2005, Pages 511-518

  Berger, Karin ^a   Ehlken, Birgit ^a   Kugland, Barbara ^a   Augustin, Matthias ^b  

^a MERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chronic psoriasis vulgaris; Cost of illness; Systemic therapy

Indexed keywords

ADULT; ARTICLE; CHRONIC DISEASE; COST OF ILLNESS; DISEASE CONTROL; FEMALE; GERMANY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHOTOTHERAPY; PREVALENCE; PSORIASIS VULGARIS; REIMBURSEMENT; RETROSPECTIVE STUDY; SKIN CARE;

ADOLESCENT; ADULT; AGED; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DRUG COSTS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PROSPECTIVE STUDIES; PSORIASIS; RETROSPECTIVE STUDIES;

EID: 21744441228     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2005.05729.x     Document Type: Article

References (23)

1. Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Austral J Dermatol 2002; 43: 255-261.
2. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46: 850-860.
3. Galadari I, Rigel E, Lebwohl M. The cost of psoriasis treatment. J Eur Acad Dermatol Venereol 2001; 15: 290-291.
4. Traupe H, Robra B. Gesundheitsberichterstattung des Bundes. Heft 11: Psoriasis. Robert-Koch-Institut Berlin 2002.
5. Finlay AY, Kahn GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
6. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J. Dermatol 1999; 141 (6): 1067-1075.
7. Scharloo M, Kaptein AA, Weinman J, Bergman W, Vermeer BJ, Rooijmans HG. Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 2000; 142: 899-907.
8. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
9. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, Clark AR. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37 (4): 564-569.
10. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 2004; 15 (1): 27-29
11. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43 (2Pt 1): 281-285.
12. Fredriksson T, Pettersson U. Severe Psoriasis - Oral Therapy with a new Retinoid. Dermatologica 1978; 157: 238-244.
13. Einheitlicher Bewertungsmaßstab (EBM) Stand: 1. Oktober 2001 [German tariff list for medical services]; Deutscher Ärzte-Verlag Köln.
14. Rote Liste. Arzneimittelverzeichnis für Deutschland [Tariff list for drugs in Germany]. Editio Cantor Verlag Aulendorf 2002.
15. Anonymus. Zahlenbericht 2001/2002. Verband der Privaten Krankenversicherer [Report 2001/2002. Association of private health insurances]. Köln 2002.
16. Statistisches Bundesamt: Fachserie 18, Reihe 1.3, 2001.
17. Finzi AF, Mantovani LG, Belisari A. Italian Association for Studies on Psoriasis: The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. JEAVD 2001; 15: 320-324.
18. Snellman E, Maljanen T, Aromaa A, Reunanen A, Jyrkinen-Pakkasvirta T, Luoma J. Effect of heliotherapy on the cost of psoriasis. Br J Dermatol 1998; 138: 288-292.
19. Hartman M, Prins M, Swinkels OQ, Severens JL, De Boo T, Van Der Wilt GJ, Van De Kerkhof PC, Van Der Valk PG. Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol 2002; 147: 538-544.
20. Berger K, Ehlken B, Kugland B, Hofmaier A, Augustin M. Quality of life in patients suffering from psoriasis vulgaris in Germany - a non-interventional survey. Values in Health 2003; 6 (6): 788 (poster presentation at ISPOR 2003)
21. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. Alefacept Clinical Study Group. A randomised, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-833.
22. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-583.
23. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-59.